Science, Technology and Medicine open access publisher.Publish, read and share novel research. Rapamycin (sirolimus) has a different mechanism of action and side effects compared to the calcineurin inhibitors (Pritchard, 2005). This research report titled “Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012-2017)” provides details about various autologous cell based treatments and their application areas. The report gives a detailed analysis about state of the art of both autologous stem cell and non-stem cell treatments. Autologous Stem Cell Therapy technology (a form of regenerative cell therapy) is changing the medicinal treatments by introducing various new therapies. Autologous Stem Cell and Non-Stem Cell Based Therapies is a novel therapeutic platform growing rapidly in the field of regenerative medicine.
Hence this technology is expected to provide immense investment opportunities in the global market. In this report, Autologous Cell Therapy is primarily segmented as stem cell and non-stem cell based therapies. Autologous Stem Cell and Non-Stem Cell Based treatments in North America are rapidly emerging as a major treatment for various incurable diseases such as Myocardial infarction, ischemic heart failure and diabetes. In Brazil and Mexico, treatments through Autologous Stem Cell and Non-Stem Cell Based Therapies for various diseases like diabetes and skin transplantation are actively progressing. In countries such as Australia, Korea, Japan and other developing nations of Asia pacific, huge investments are being for developing the Autologous Stem Cell and Non-Stem Cell Based Therapies treatments for various incurable diseases. Consistent with the pathophysiology and symptoms of stroke, stroke is a leading cause of adult impairment, with 20% of stroke survivors requiring institutional care after 3 months and up to 30% being severely and permanently disabled.
The only approved treatments of acute ischemic stroke involve restoring blood flow to the affected region by using thrombolytics or mechanical devices that physically remove clots. Following the completion of a stroke, there is little therapy to offer patients to promote recovery other than physical, occupational, and speech therapy. Stroke ranks as the country’s third leading cause of death, behind only cancer and heart disease. Stem Cell Application Mexico: What Does It Mean to be a BioHeart Stem Cell Center of Excellence? London, Sept 6 : Loss of stem cells during chemotherapy or radiation therapy is the main side effect for human cancer patients, leading to anaemia, appetite and weight loss.
The loss of adult stem cells is particularly dangerous, as they are the ones responsible for making new blood and intestine cells.
They’ve also known that a gene called Puma is critical for p53 to initiate the cell death of DNA-damaged cells, reports Nature.
The team published its findings in this week’s advance online issue of the journal Nature Cell Biology. SoRelle1 and Bashoo Naziruddin1[1] Institute of Biomedical Studies, Baylor University, Waco, Texas, and Baylor University Medical Center, Dallas, Texas,, United States of America1. Although rapamycin binds to FKBP12 in a similar mechanism like tacrolimus, it does not inhibit calcineurin, rather the complex inhibits mTOR (mammalian Target Of Rapamycin). Every health regulatory bodies will be expecting companies and universities to develop therapy treatments, which are Safer, Affordable, Robust, Rapid, Easy to use, Effective and Deliverable to the end user.
It includes the current advances and applications of the technology and trends in terms of market size and growth of autologous cellular therapies in medical treatments globally. It is considered to be an effective and safer technology in comparison with the existing transplant technologies such as allogeneic and xeno transplants.
Stem cells have the potential to develop into many types of cells in the body during the early stage of life and also serve as an internal repairing system; therefore the number of treatments based on stem cells is comparatively higher than non-stem cells.
Recently RNL Bio, Korean company has been providing stem cell treatments for patients in Korea and Turkey.
However, the use of thrombolytics (tPA) is limited due to the therapeutic window of < 3-6 hours post onset of stroke symptoms such that only a small fraction of stroke patients receive this therapy, thus effective prevention remains the best treatment for reducing the burden of stroke. Scientists have long known that during cancer therapy, the tumour suppressor p53 is activated, which leads cells to stop dividing, go into hibernation and undergo a programmed cell death called apoptosis. Green colored arrows indicate opportunities and the red colored hammer indicates challenges. Introduction Type 1 Diabetes mellitus (T1D) is an autoimmune disorder caused by destruction of pancreatic beta cells which produce insulin. This inhibits the second phase of T-cell activation, whereas tacrolimus and cyclosporine inhibit the first phase. Autologous stem cell transplantation for particular application areas is safe experiencing robust growth and has minimal steps of procedure to follow and is rapid in deriving the results. It also consists of funding details of the innovative therapy and recent activities in terms of mergers & acquisitions of the company and revenue forecast.
Autologous transplants facilitates in reduction of risks associated with bio-incompatibility, disease transmission and immunological reactions. This report explains the potential therapeutic areas of ACT such as Neurodegenerative, Cardiovascular, Cancer and Autoimmune diseases, Skin transplantation and Infectious diseases. So rapamycin also inhibits signal transduction leading to IL-2 production and clonal proliferation, and since it affects a different part of T-cell activation it can be used synergistically with calcineurin inhibitors. The sources for autologous stem cell therapy are Mesenchymal stem cells, Hematopoietic stem cells, Chondrocytes and so on. It includes latest autologous cultured cell treatment details and products which are available for licensing and approvals from various regulatory bodies. Autologous Stem Cell and Non-Stem Cell Based Therapies market is currently estimated as $650 million, including products of all application areas.
It gives detailed information about current advances and applications of Autologous Cell Therapy technology and trends in terms of market size and growth of autologous cellular therapies in medical treatments globally. The data available so far from human and animal research is encouraging, but it does however have enormous limitations.The researchers advised establishing what kind of stem cells, bone marrow, placenta-derived or hematopoietic, could be best for treating type 2 diabetes. Recent data compiled by the American Heart Association (AHA) for 2008 show that the annual incidence of new or recurrent stroke in the United States is about 780,000, with approximately 600,000 of these strokes being first attacks. One of the side effects associated with this drug is oral ulcers that make ingestion of food difficult. Currently, the cost of the treatments is not affordable however, by the intrusion of government bodies, this mode of treatment will certainly experience an immense market growth.
Using drivers, restraints and challenges, the market revenue is forecasted for a period of five years, i.e.
It explains the principle of the therapeutic products of various companies working in this sector. Post-transplantation individuals also required close monitoring for neoplasia as stem cells, pluripotent or multipotent, have the potential for malignancy. Rapamycin is thus a potential alternative or adjunct to calcineurin inhibitor mediated T-cell inhibition.Another widely used immunosuppressant is mycophenolate mofetil, MMF, which prevents B and T-cell proliferation (Ransom, 1995).
ACT has already been successful in the treatment of prostate cancer, skin burns, cosmetic surgeries, skin substitutes, wound healing, pressure ulcers, etc.
However, this treatment has several limitations including development of secondary health complications over time.
This is the first of two enzymes responsible for the production of guanosine monophosphate from inosine monophosphate; lymphocytes are particularly dependent on this pathway for the subsequent synthesis of GDP, GTP, and dGTP. Opportunity strategy evaluation has been included which gives information on potential application areas for investments. The reduction of GTP and dGTP levels in lymphycytes results in a decreased ability to perform DNA synthesis and GTP dependent metabolism.
Some of the adverse events associated with this drug include nausea, infections, leucopenia, and anemia. This alternative mechanism of specific immune system suppression has led to the widespread use of MMF in combination with tacrolimus or sirolimus. These numbers are limited, because the drug being tested, Efalizumab, was withdrawn from the market during treatment. Diabetes comes from an ancient Greek word coined by Arataeus of Cappadocia, and mellitus from the Latin word honey associated with sweet urine.
This study was compared to the original Edmonton protocol which used daclizumab for induction and a combination of tacrolimus and sirolimus as seen in Table 1.
Currently the mechanism that triggers this disease is still unknown, but it seems to be a combination of environmental and genetic factors. The mechanism underlying this tolerance seemed to be linked to a unique donor specific IL-10 regulated immune response, leading to improved insulin independence rates. T-cells in the host’s body become sensitized to protein that naturally occurs in the beta cells of the pancreas and the immune system begins to mount a specific attack leading to destruction of the islets of Langerhans. There have also been several antibody mediated approaches to preventing T-cell activation by blocking costimulation.
Reducing the autoimmune effect in beta cell replacement is very important, but before moving onto the strategies for beta cell replacement therapy it is important to describe the standard therapy for T1D and how it falls short of providing for all the needs of diabetic patients.Exogenous insulin therapy continues to be the leading therapy for T1D today, but there are several complications associated with it. However, even intensive monitoring of blood glucose and injection of insulin is not enough to halt the secondary complications of diabetes (Harlan et al., 2009). Unfortunately, this therapy cannot be continued, because efalizumab was withdrawn from the market by the FDA in mid 2009 (Posselt et al., 2009).
Lowered blood sugar levels, which can result if too much insulin is administered, can also lead to a hypoglycemic episode (Cooke and Plotnick, 2008).
Despite the progress made, any use of immunosuppressants will slow the widespread applicability of islet transplantation, since the cost benefit analysis of immunosuppression must be compared to insulin therapy alone. These episodes are typified by ketoacidosis, where in an effort to find energy, the body burns fatty acids leading to the production of acidic ketones that can be detected by an alcoholic smell on the breath.
Hypoglycemic episodes can lead to coma and even death, and is considered the most severe side effect of diabetes. Xenogenic porcine islets for transplantationEven if all pancreatic islet cell transplantations became successful and only required one pancreas to achieve insulin independence, there would still be an insufficient number of pancreata to treat all type 1 diabetic patients.
Secondary complications such as blindness, peripheral neuropathy, and cardiovascular complications result from destruction of microvasculature. There are approximately 7,000 pancreases available for donation in the United States per year, but diabetes milletus affects as many as 3 million people in the United States and as many as 16 million people worldwide. Additionally, the quality of life is lower even for patients with well regulated blood sugar. This shortage in human islet cells from organ donor sources has led to a search for alternative sources (Hering & Walawalkar, 2009). There are several methods both clinical and experimental that are being developed to provide optimal beta cell replacement.
The first type that was developed and successfully applied to the clinical setting was that of whole organ pancreas transplant (WOP). Through genetic engineering of pig herds, a knockout animal which lacks this epitope has been successfully bred (Puga Yung et al., 2009). Next, in an effort to transplant only the insulin secreting portion of the pancreas, islet transplantation was explored and has been applied through several clinical trials. However kidney transplantation results using this animal have shown only modest gains.Another fear of porcine islet transplantation is that pig endogenous retrovirus (PERV) could be transmitted from the porcine islets transplanted into the human recipient. Efforts have been made to improve this technique by perfecting the techniques of islet isolation and immunosuppression; immunoisolation and xenotransplantation are also being explored.
Although pigs can be bred in pathogen-free facilities that shields them from contracting microbes that can be transmitted, PERV is integrated into the genome and the risk of infection cannot be so easily removed.
However, even if all donor human pancreases were effectively used, they would be insufficient to treat every patient eligible for transplant. When recipients are immunosuppressed, porcine cytomegalovirus or pig lymphotrophic herpes virus are common infections that can be activated under immunosuppression.
This emphasizes the importance of current studies into beta cell regeneration from many sources including embryonic stem cells, and pancreatic ductal and acinar cells. There have been conflicting reports of PERV manifesting in non-obese diabetic mice transplanted with pig islets.
For humans, sensitive detection techniques such as quantitative polymerase chain reaction or immunoblotting assays for PERV proteins.
Pancreas transplantationTransplantation of whole allogenic pancreas is an established procedure. The first clinical transplant of a whole vascularized pancreas was at the University of Minnesota in 1966. Initial results showed very poor graft survival rates; less than 5% of grafts survived after six months. The Mexico trial involved transplantation of collagen generating devices embedded with islet and sertoli cells into twelve juvenile type 1 diabetic patients.
Because the pancreas is a very large, immunogenic organ, large doses of immunosuppressants are required to prevent rejection. This procedure did not produce long term insulin independence, but glycemic control was improved along with positive porcine C-peptide in patient urine during long term follow-up.

Immunosuppression protocols had to be adjusted to prevent graft rejection while not being so strong as to damage the beta cells.
A second noteworthy clinical trial is being performed in New Zealand using alginate encapsulated neonatal porcine islets transplanted into the peritoneal cavity of type 1 diabetic patients. However, the addition of mycophenolate mofetil and tacrolimus to regimens suppressing the immune system dramatically increased the success of whole pancreas transplant from 20% to 80% survival after one year.
The pigs used were raised in pathogen-free facilities with a donor herd free from conventional pathogens and non-transmittable PERV.
This unique lack of exposure to viruses is a characteristic of these pigs which were raised on the island of New Zealand with limited exposure to foreign diseases.
The addition of sirolimus, an immunosuppressant lacking nephrotoxic or beta cell toxic properties, along with an antilymphocyte antibody induction allowed the discontinuation of steroids from maintenance therapy.
In terms of xenogenic related infection, zoonosis has been rigorously monitored with no evidence of cross-species infection. Again, no patients became insulin independent, but there was a significant reduction in hypoglycemic unawareness episodes. Three year survival rate, defined as insulin independence, is around 80% according to the International Pancreas Transplant Registry (Gruessner, 2001). This encapsulation method demonstrates the usefulness of immunoisolation in islet transplantation (Elliott RB, 2011).Porcine islets have been used to explore alternative transplant sites, since blood in the portal vein of the liver often contains higher concentrations of immunosuppressants and other toxins, while containing low concentrations of oxygen.
Transplanting a whole pancreas simultaneously or after a kidney transplant has provided significant improvement in patients. Areas of porcine islet transplantation into non-human primates include intraperitoneum, renal subcapsule, subcutaneous, the omentum pouch, and the mesentery (Hering & Walawalkar, 2009).
Since diabetes affects the function of the renal system, many patients will have a history of dialysis. The efficacy of each transplant site is difficult to determine as various immunosuppressive therapies were used in addition to encapsulation and the use of a subcutaneous mono-layer device. Such an issue would call for a kidney transplant, and since this would already require a surgical procedure and immunosuppression, adding a pancreas transplant in a simultaneous fashion could prove beneficial (Humar et al., 2000).
These large animal studies have shown some success demonstrating the ability in some cases to create insulin independence with immunosuppressants. In fact, the development of secondary complications is attenuated by an allogenic pancreas transplant. Further, the progression of nephropathy is decreased from diabetic effects with the simultaneous transplant of a pancreas and kidney. Islet ImmunoisolationThe leading strategy to reduce or eliminate the most risky aspect of islet transplantation, namely immunosuppression drugs, is immunoisolation.
There also appears to be improvements to the quality of life and in the damage to the peripheral nerve system (Venstrom et al., 2003). To protect islets from the recognition of the immune system, two strategies have been used, specifically encapsulation and surface modification (Wilson & Chaikof, 2007) as shown in Figure 1. Although transplant of whole allogenic pancreases offers the above advantages, it comes with the serious complications associated with surgery. Encapsulation involves, as its name suggests, enclosing an islet in a capsule that is impermeable to the immune system. A study by the Univeristy of Pennsylvania (Frank et al., 2004) compared 30 whole pancreas and 27 isolated islet transplants.
This investigation showed that 7 patients (23%) required post-transplant surgery while only 1 islet recipient (7%) needed surgery. The capsules must have defined pore sizes that allow the influx of glucose as well as the secretion of insulin, while simultaneously preventing intrusion by complement or antibodies.
There was a significant difference in the number of patients requiring blood transfusions post-transplant from whole pancreas (43%) versus islet transplant (7%). The main reason that would account for the differences in surgical complications can be attributed to the invasiveness of the whole pancreas transplant versus the relatively non-invasive islet transplant, which is performed by percutaneous puncture and infusion into the portal vein of the liver.
EncapsulationThe encapsulation method is limited by bioincompatibility and biodegradation of the materials in addition to hypoxic damage to the islets (Lee & Byun, 2010). Thus long hospital stays are required of whole pancreas transplant cases whereas islet transplantation is an outpatient procedure leading to a lower estimated cost. Further there is the practical limitation of size; the typical islet diameter of 150 µm is often increased by as much as 5 fold, leading to a volume increase greater than 100 fold. Despite the lower surgical risk and cost of islet transplantation it has not yet achieved the duration or rate of graft success found in whole pancreas transplantation.
Since more than 500,000 islet equivalents are now required to cure diabetes (~10mL islet pellet volume), that volume would be increased to over 1 liter with encapsulated islets.
An issue for beta cell replacement is the low number of donors compared to the number of eligible recipients (Matsumoto et al., 2006).
This would exclude transplantation into the portal vein of the liver, because this volume of islets would significantly increase the risk of portal vein thrombosis and other bleeding complications.
In the United States, there are an estimated 7,000 available donor pancreases, but the number of pancreases available for clinical transplant are much lower due to many exclusion criteria.
Thus, alternative sites of injection such as subcutaneous, intraperitoneal, or intramuscular have to be validated. However, this technique still would have the issue of incomplete encapsulation or variable number of islets entrapped.
Although the islets received from young donors are suggested to display greater functionality, it is very difficult to effectively isolate a sufficient number of islets for transplant from these donors.
Surface modification An alternative to macroencapsulation is surface modification, which uses the islet surface as the scaffolding upon which to build protective barriers. Conversely, isolations from pancreata from older, obese (BMI>30) donors produce higher yields of islets that are still functional and qualify for clinical transplant. Thus islet transplant has the ability to utilize marginally acceptable pancreases for clinical transplant, increasing the ability to perform beta cell replacement. These non-overlapping criteria for whole organ and islet isolation reinforce the notion that these two treatments are not competitive, but rather complementary.The important advances and improvements of whole organ pancreas transplant over the past two decades have given significant momentum to this method of beta cell replacement in patients with life-threatening diabetes.
Another method of surface modification is PEGylation, which attaches long chains of PEG, a hydrophilic, biologically inert, flexible polymer chain.
Although the one year rejection rate is higher at 8% for solitary pancreas transplant in preuremic patients than the rejection rate of 2% seen in persons receiving simultaneous pancreas and kidney transplants, the increased success of the procedure still warrants its application (Gruessner, 2001). However, this treatment is still limited to patients with brittle diabetes experiencing uncontrolled blood glucose levels and hypoglycemic unawareness despite intensive insulin therapy.
These experiments show that surface PEGylation of islets can be accomplished successfully without loss in viability or functionality. The risk of morbidity, the need to open the abdominal cavity during surgery, and the strong immunosuppressive regimen required for solid organ transplant substantiates a long, hard look at alternative methods of beta cell replacement. One of the main advantages of PEGylation to islets is that there is no significant size increase like that associated with macroencapsulation. There is only a microscopic increase in size, because the PEG conjugated islets (PEGylated islets) are modified at the molecular level.
Islet cell transplantationThe transplantation of pancreatic islets of Langerhans is an exciting alternative, because it reduces the surgical risk of complication by being less invasive (Frank et al., 2004). The traditional and most widely used PEGylation technique applied uses a succinimidyl functionalized PEG (N-hydroxysuccinimide, NHS), which reacts to surface amine groups on the islet surface (Lee et al., 2007). Furthermore, transplanting only the functional, insulin secreting portion of the pancreas reduces the risk of activating the exocrine, digestive portion of the pancreas, which could lead to deterioration of endocrine function. However, there are several other surface moieties that can be targeted by chemical modification. One such possibility is the ability to manipulate islets prior to implantation to protect them from the immune system or to attach biologically active molecules that could aid in engraftment. This same study also analyzed optimization of surface modification by varying reaction time and concentration of the functionalized PEG; the new oxidative method was even combined with the traditional NHS method. Xenogenic, porcine islets could also fill the gap between beta cell supply and demand (Hering & Walawalkar, 2009). Another poorly studied aspect of islet surface modification is in relation to the longevity of the modification methods. Each of these methods contains complicating factors that do not allow current application to the clinical setting, but recent advances have put them closer in reach than ever before.A comparison of the historical progress of whole organ transplant to that of islet transplantation would provide an objective basis to evaluate the progress of islet transplantation. The islet surface is a dynamic environment, with constant turnover and regeneration of the cell membrane. Although whole organ treatment achieved high levels of graft survival in the years 1994-1997, the islet survival rate at five years has reached around fifty percent in 2010-2011, comparable to the level of whole pancreas graft success (Rickels et al, 2011).
Almost all of the PEGylation techniques mentioned only look at the uniformity and quantity of the PEG immediately after modification.
If PEG is supposed to protect islets from the immune system, it should be robust and remain for a long time in order to protect islets from T-cell mediated rejection.
Breakthroughs have been made in the area of pancreas procurement and preservation with study into ductal preservation, the two layer method, and the type of preservation solution used.
Furthermore, there has been much progress in the islet isolation process by bringing standards up to cGMP qualifications, optimization of collagenase enzymes, and using iodixanol for continuous density gradient purification (Matsumoto et al., 2009). Beta cell regenerationDevelopment of type 1 diabetes is a consequence of loss of functional beta cell mass.
Pancreas preservation and islet isolationThe islet isolation process is fundamental to islet transplantation. Hence the objective of many therapeutic approaches to treat T1D is to restore beta cell mass sufficient to maintain normoglycemia. The main stages in isolation are pancreas procurement and preservation, digestion of the organ, and purification of the islets.
First, the pancreas is obtained from the organ procurement organization, prepared with certain preservation solutions and injections as described later. In a healthy individual, the beta cells lost are constantly replenished by beta cell neogenesis through mechanisms which are not clearly understood. Upon arrival at the isolation facility, the pancreas is disinfected and injected with a digestion enzyme that degrades the pancreas and releases islets. Beta cell mass is maintained and regulated in response to pharmacological and nutritional stimuli which include glucose, insulin, epidermal growth factor (EGF), gastrin and glucagon like peptide (GLP-1).
Lastly, the mixture of pancreatic tissue is centrifuged with a density gradient to separate the endocrine tissue from the exocrine tissue. Physiological stimuli such as pregnancy, obesity and pancreatic tissue damage also significantly regulate beta cell mass.
An important requirement of cGMP facilities is the validation and sterilization of all equipment (Garfinkel et al., 2004). Although initially assumed to increase the cost of establishing an islet isolation program, the guidelines of cGMP ensure the efforts of improving safety of islet preparations.
Documentation of errors, corrective measures, and preventative actions minimize costs and provides the ability to critically evaluate the impact of certain actions. Validation of instruments prevents false bias readings, and validation of processes indicates whether assumptions about the production are correct or not (Yamamoto et al., 2009). Documentation not only proves the correctness of the manufacturing, but also provides data for scientific reports. Pancreas preservation In the area of organ preservation, damage due to low oxygenation and warm ischemia are important hurdles to overcome.
Warm ischemia is the time between the cessation of a heart beat in a donor’s body and when cold preservation solutions can be injected. Ischemia is the loss of blood circulation to an organ that consequently causes a lack of oxygen, glucose, and other helpful molecules in the blood. In general, warm ischemia times greater than fifteen minutes cause pancreases to be of marginal quality and times exceeding thirty minutes usually disqualifies the organ for transplantation. Significant amounts of damage are incurred to the pancreas and islets during warm ischemia time, but cold ischemia time should also be limited as much as possible. Cold ischemia time is incurred during procurement and transportation of the organ, and should be lower than twelve hours. In addition to ischemic injury, there is also the danger of hypoxic damage from low oxygenation conditions (Sawada et al., 2003). Following procurement, donor pancreases were initially preserved in University of Wisconsin solution (UW) or Histidine-Tryptophan-Ketoglutarate solution (HTK). Although these solutions are standard for tissue preservation of other organs, other preservation methods were attempted to improve the results of islet isolation. The two layer method and ductal preservation have emerged as two techniques that preserve the pancreas while leading to increased islet yield and quality from isolation.The advent of perfluorocarbon as an excellent oxygen carrier led to significant improvements in reducing hypoxic damage. Perfluorocarbon (PFC) is a hydrocarbon derived chemical where all of the hydrogens of a carbon chain are replaced by fluorine atoms. The uniform covering of fluorines prevents polarization of the electron clouds, which explains the low van der Waals forces and non-polar nature of the molecule (Lamal, 2004).
The property of PFC that makes it particularly attractive as an organ preservation and oxygenation solution is the capacity to dissolve large amounts of oxygen.

This high dissolving power of PFC combined with a low oxygen binding constant, due to low intermolecular forces, allows PFC to release oxygen more effectively than hemoglobin (F2 Chemicals Ltd., 2003). The addition of a water based preservation solution above the PFC solution prevented the loss of dissolved oxygen (Matsumoto & Kuroda, 2002).
The distinction between the static and original TLM is that the original method provides continuous oxygen supplied to the PFC, while static method precharges the PFC with oxygen before the organ is added. Islet yield, viability, and functionality were significantly improved by both two-layer methods compared to UW solution alone. This study showed that the islet yield, viability, and in-vitro function were significantly improved by both TLM approaches with similar results. Since the static TLM is easier and yields comparable results as the original method it has subsequently attained widespread use in clinical studies.
In contrast, a larger study comparing the effectiveness of TLM vs preservation in UW solution alone reported no significant advantage in using TLM method (Caballero-Corbalan et al., 2007)Although this TLM is effective at oxygenating the pancreas, the organ is still a thick tissue with inner, non-accessed parts being exposed to a higher risk of damage. It has been hypothesized that the ductal system is thus especially susceptible to cold ischemic injury. This could result in the inability to properly perfuse collagenase (an essential reagent discussed later) by intraductal distention.
By injecting cold preservation solution in the opposite direction through the main pancreatic duct, a majority of the inner spaces of the pancreas can be reached, preserving a greater number of islets for isolation, and allowing greater distention of the organ during collagenase injection (Matsumoto et al., 2002).
Functionality results for islets isolated from pancreata receiving ductal injections of cold preservation solution were evaluated by an in-vivo assay, insulin secretion, and by viability testing. Ductal preservation significantly reduced the number of nonviable cells from around sixty percent to lower than twenty percent.
The best determinant of islet quality is the in-vivo assay, which involves the transplantation of isolated islets under the kidney capsule of a diabetic nude mouse. This further confirmed that islets not preserved with ductal injection could not cure diabetic mice in any of the cases, whereas islets from pancreata perfused with UW solution showed a similar curative rate compared to islets from a fresh pancreas (Sawada et al., 2003).
Protecting the pancreas from ischemic damage between procurement and processing is an important aspect of islet isolation. Although islets only constitute about 2-5% of the total pancreatic mass, they use over 10% of the organ’s blood supply.
Successful human islet isolations hinge upon the quality of the collagenase used, which is the blade that cuts islets from the pancreas providing isolated islets.
The types of collagenase traditionally used are derived from Clostridium histolyticum (Linetsky et al., 1997).
Liberase HI provided the advantage of not only higher islet yields compared to crude collagenase, but also a reduction in contaminating enzymes and endotoxin.
Despite these advantages, Liberase HI appeared to have inconsistencies between lots, and exhibited poor storage stability (Barnett et al., 2005).
This enzyme blend further fell out of favor, because animal products such as bovine brain extract were used in the manufacturing process (Shimoda et al., 2010). Results from many centers that used this enzyme are mixed in terms of generating islet yields and quality similar to those achieved by Liberase HI (Barnett et al., 2005, Yamamoto, 2007). The results of these isolations show that VIzyme produced significantly higher yields of islets. The final islet equivalent (IEQ) per gram of pancreas for VitaCyte enzyme versus Serva’s enzyme was 414,700±175,900 versus 213,400±152,400 with a p value of 0.002.
Islet equivalent (IEQ) is the standard unit of measurement of islets and corresponds to a round islet with a diameter of 150 micrometers. Two patients received islets isolated from Serva’s NB-1; one patient achieved normoglycemia for over 700 days and the other had evidence of graft failure on day 84. Of four patients transplanted with islets isolated using collagenase from VitaCyte, three were insulin independent for more than 350 days. Although this clinical data is not conclusive, it does demonstrate that the utilization of VIzyme in islet isolation may prove beneficial to increasing islet yields. PurificationThe final stage in the islet isolation process is purification to separate functional islets, from the contaminating acinar cells.
However, one disadvantage is that the islet post-purification recovery is mostly decreased. The traditional gold standard for this process was the use of Ficoll, a heavy, multi-branched sugar that readily dissolves in water, based density gradient combined with semiautomated centrifugation with a COBE-2991 cell processor to achieve optimal results (Matsumoto et al., 2006). The centrifugation process can be mechanically stressful and damaging to islets; further the exposure to enzyme and endotoxin in the isolation can lead to apoptosis, inflammation, and attack by the immune system post-transplant. An alternative density solution, iodixanol, is a neutral iso-osmotic contrast solution used clinically in the imaging field. Iodixanol’s effect on the purification was studied along with the production of pro-inflammatory cytokines after islet isolation (Mita et al., 2010). Islets purified by iodixanol-based gradients yielded significantly lower levels of cytokines and chemokines when compared to Ficoll-based gradient solutions. The inflammatory molecules that were downregulated include interleukin-1 beta (IL-1?), tumor necrosis factor-alpha (TNF-?), interferon-gamma (IFN-?), IL-6, IL-8, macrophage inflammatory protein 1beta(MIP-1?), and monocyte chemoattractant-1 (MCP-1). These cytokines are known to not only be pro-inflammatory, but some are also associated with apoptosis and necrosis. These results provide compelling data that iodixanol has a protective effect on islet preparations when used in density gradient purifications. In the Edmonton protocol (2000), islets were transplanted immediately after isolation, without a period of culturing. Although this may cause attrition of islets, some argue that the culture period allows damaged ineffective islets to die off while permitting enough time for functional testing of islets prior to transplantation. Further, the culturing period could be used to pretreat the recipient or the islets themselves. The culture of islets up to 48 hours pre-transplant has gained some popularity for several reasons. This culture time allows depletion of apoptotic islets and testing for sterility, microbiology, viability, and in vitro glucose stimulated insulin secretion response. The patient does not have to be rushed into a radiology suite to receive the infusion, but this time could allow for the start of an immune cell depleting induction therapy.Thus, the advances made in the area of islet isolation have been substantial over the past decade. The standardization to cGMP facilities, preservation with the two layer method and ductal injection method have all improved the preparative conditions for conducting an isolation. The optimization of the collagenase solution continues to improve islet yields after pancreatic digestion. By currently using iodixanol based density gradient solutions, the risk of apoptotic islet damage both after isolation and after transplantation has been reduced by the lowering of inflammatory cytokines. Advances in immunosuppression to prevent islet graft rejectionAlthough it is difficult to obtain islet preparations of an adequate quantity and quality for transplantation, it is also very difficult to protect and maintain the allogenic islet function after transplantation. There are several aspects of the immune system that prevent the long term survival of islet cells. The first reaction encountered by islets is the instant blood mediated inflammatory response (IBMIR), primarily mediated by the innate immune system which leads to islet destruction (Bennett et al., 1999). Islets surviving this initial, short term inflammatory response are later subjected to targeting of autoimmune and alloimmune responses. The autoimmune response which already exists in type 1 diabetic recipients, being the source of the pathogenesis of the disease and is specifically reactive to beta cell markers such as glutamic acid decarboxylase (GAD65) and islet cell antigen (ICA) (Shapiro et al., 2003).
Immunosuppressive regimens for islet cell transplant recipients must counter these aspects of the whole immune response for improved graft survival.Immunosuppression after islet transplantation is comprised of two phases namely induction and maintenance therapies. The maintenance drug regimen is focused on suppression of T-cells by various strategies including calcineurin inhibitors such as tacrolimus, and cyclosporine. Beta cells naturally have lower levels of anti-oxidant enzymes, which put them at an increased risk.
Further, the hepatic graft site puts islets in contact with blood that has higher concentrations of the immunosuppressive drugs, increasing any negative side effects. The advent of the Edmonton protocol demonstrated successful islet transplantations, with a part of the accomplishment being attributed to minimizing calcineurin inhibitors and a steroid-free induction process.
Induction therapyThe first stage of treatment for islet transplantation is the induction therapy that attempts to reduce the inflammatory effects of the short term immune system. It has been estimated that during the initial phase after transplant, as much as 50 to 60% of the islets graft is lost due to IBMIR (Bennett, 1999). Within as little as five minutes, natural IgG and IgM lead to complement activation starts to attack it by creating perforin complexes that lead to cell lysis (Tiernberg, 2008).
Another significant physiological change involved in IBMIR is the dramatic, rapid increase in cytokine levels such as IL-2, TNF-?, IL-1?, and IFN-?. Due to diabetogenic effects glucocorticoids are avoided in the immunosuppressive regimens turning to newer alternatives (Shapiro et al., 2000).
An alternative to steroids is daclizumab, a humanized monoclonal antibody with specific affinity to the IL-2 receptor.
This receptor on T-cells is responsible for the main activation pathway, which triggers an immune response against beta cells.
This thymoglobulin is a polycolonal antibody that targets T-cells, thus depleting the cells required to mount a specific response to islets even before they enter the body.Another T-cell depleting agent used for induction therapy is alemtuzumab (Maggliocca, 2006).
Alemtuzumab is a monoclonal antibody against CD52, which is a marker of mature lymphocytes. One specific complication is that it increases the chance of infections while also increasing the possibility of reactivation of cytomegalovirus.Another target of induction therapy includes the proinflammatory cytokine response. Additionally TNF-? blockage was shown to significantly improve the clinical outcome of patients based on the collaborative islet transplant registry (CITR) database (CITR Report 2009). To abrogate the inflammatory effects of these cytokines a combined treatment of eternacept and anakinra was used for induction therapy (Matsumoto, 2011).
Etanercept is a TNF-? inhibitor, acting as a decoy receptor and blocking the true effect of TNF. All patients undergoing this therapy were able to achieve insulin independence following a single islet infusion.
Gene microarray analysis was performed on blood samples taken within the first week post-transplant. The results of the gene microarray demonstrated that genes related to cytotoxic T cells were repressed; however, there was upregulation seen in inflammation and neutrophil related genes. This suggests that there may be alternative inflammatory cytokines and agents that may be relevant to the immediate immune reaction. Inhibition of NF-kB to prevent inflammationInstead of trying to target all of the extracellular agents that might cause an inflammatory reaction, an effort was made to find and inhibit a downstream signaling protein that is activated by pro-inflammatory cytokines. Nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-?B) is a protein that regulates transcription of several sequences of DNA and is activated through a canonical pathway by inflammatory cytokines (Hawiger, 2001). This led us to believe that inhibition of NF-?B would inhibit the collective effects of circulating cytokines. An inhibitor of NF-?B activation was found in traditional eastern medicine from the plant Withania somnifera extract called Withaferin A, WA (Kaileh et al., 2007). WA was not shown to decrease islet viability or functionality, while simultaneously inhibiting the inflammatory response.
This study showed higher retention of insulin independence in a xenogenic model when a proprietary NF- ?B inhibitor drug was injected once, thirty minutes before the transplantation. The primary anticipated effect of NF- ?B inhibition is on the IMBIR reaction which is more easily studied in a syngenic model, where the only source of graft failure is IBMIR rather than a specific adaptive immune response. Maintenance therapyThe purpose of the maintenance therapy is to suppress the specific alloimmune and autoimmune responses mediated by T and B lymphocytes. The drugs typically used for this purpose include Prograf, Rapamycin, MMF, and blockers of co-stimulation. Several combinations of these therapeutic agents have been attempted in clinical islet transplantations to increase the longevity of the graft while minimizing the beta cell toxicity and patient related adverse events.The types of immunosuppression traditionally used for transplantation are the calcineurin inhibitors tacrolimus and cyclosporine, but often these agents were associated with toxic effects for beta cells (Drachenberg, 1999). The original molecule was found in the fermentation of a soil sample containing the bacterium Streptomyces tsukobensis (Pritchard, 2005). Tacrolimus inhibits the activation of NF-AT and its translocation to the nucleus by forming a complex with the immunophilin FKBP12 to inhibit the activation of calcineurin and subsequent T-cell activation (Liu, 1991).
This action also leads to the arrest of the cell cycle, preventing it from moving from the G0 stage to the G1 stage; thus cellular proliferation is prevented. This is a serious implication for a transplantation procedure trying to prevent this very condition. This side effect was histologically analyzed in solid pancreas transplants for patients receiving either tacrolimus or cyclosporine in a randomized fashion (Drachenberg, 1999). Sectioned biopsy samples from 1 to 8 months post-transplant revealed cytoplasmic swelling,vacuolization, apoptosis and irregular insulin staining of islets for patients receiving both drugs. But as this study shows it should be administered in low doses to prevent beta cell toxicity.

Medical errors prevention & reporting for dietitians
January 1977 year of the chinese zodiac



    Observe when their pet has diagnosed with.


  2. SKA_Boy

    From your diet will not get hungry hours before important to our body's composition, we are.


  3. Real_Sevgi

    Brown rice 40 grams will stays a preferred staple in the ketogenic weight loss program with a very.


  4. milaska

    Carb BBQ sauce, or a mix of mayo the country for its effective, safe and follow.


  5. GOZEL_2008

    Medicines shouldn't do the diabetic mediterannean abdomen rather than your hips probably present more often than.